With two approved drugs and close to 300 clinical / preclinical product candidates *Roots Analysis*

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

 

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

 

The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:

  • Therapeutic Area
  • Autoimmune Disorders
  • Eye Disorders
  • Genetic Disorders
  • Hematological Malignancies
  • Infectious Diseases
  • Inflammatory Disorders
  • Skin Disorders

 

  • Mechanism of Action
  • Cytokines Retargeting / Neutralization
  • Dual Ligands Blocking
  • T-cell Retargeting / Activation
  • Others

 

  • Target Antigens
  • CD3 x CD19
  • CD30 x CD16A
  • Factor IXa x Factor X
  • IL-1α x IL-1β
  • IL-13 x IL-4
  • IL-17A x Albumin
  • IL-17A x IL-17F
  • Psl x PcrV
  • VEGF-A x ANG2
  • Others

 

  • Antibody Formats
  • Asymmetric
  • Fragments
  • Symmetric
  • Others

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific

 

The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Amgen
  • Ablynx
  • AbbVie
  • Affibody
  • Affimed
  • Alphamab
  • AstraZeneca
  • Avillion
  • Chugai Pharmaceuticals
  • Eddingpharm
  • GSK
  • Merck
  • Merus
  • Roche
  • Regeneron Pharmaceuticals
  • Taisho Pharmaceuticals
  • Zymeworks

 

Table of Contents

 

  1. Preface

    2. Executive Summary

  2. Introduction
  3. Market Overview
  4. Bispecific Antibody Therapeutics: Technology Platforms
  5. Drug Profiles
  6. Key Insights
  7. Benchmark Analysis: Big Pharma Players
  8. Partnerships and Collaborations
  9. Contract Services for Bispecific Antibody Therapeutics
  10. Clinical Trial Analysis
  11. Case Study: Regulatory Guidelines for Bispecific Antibodies
  12. Case Study: Promotional / Marketing Strategies
  13. SWOT Analysis

 

  1. Market Forecast and Opportunity Analysis

 

  1. Concluding Remarks

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com